Irwindeep Sandhu

4.1k total citations
65 papers, 482 citations indexed

About

Irwindeep Sandhu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Irwindeep Sandhu has authored 65 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 32 papers in Molecular Biology and 29 papers in Oncology. Recurrent topics in Irwindeep Sandhu's work include Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (19 papers) and Acute Myeloid Leukemia Research (12 papers). Irwindeep Sandhu is often cited by papers focused on Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (19 papers) and Acute Myeloid Leukemia Research (12 papers). Irwindeep Sandhu collaborates with scholars based in Canada, United States and Spain. Irwindeep Sandhu's co-authors include Paul C. Grimm, Anette Melk, Philip F. Halloran, Wipawee Kittikowit, K. Halloran, Bernhard M. W. Schmidt, Christopher P. Venner, Michael P. Chu, Ann Lee and Andrew R. Belch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Irwindeep Sandhu

53 papers receiving 473 citations

Peers

Countries citing papers authored by Irwindeep Sandhu

Since Specialization

Citations

This map shows the geographic impact of Irwindeep Sandhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irwindeep Sandhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irwindeep Sandhu more than expected).

Fields of papers citing papers by Irwindeep Sandhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irwindeep Sandhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irwindeep Sandhu. The network helps show where Irwindeep Sandhu may publish in the future.

Co-authorship network of co-authors of Irwindeep Sandhu

This figure shows the co-authorship network connecting the top 25 collaborators of Irwindeep Sandhu. A scholar is included among the top collaborators of Irwindeep Sandhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irwindeep Sandhu. Irwindeep Sandhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Hira Mian, Alissa Visram, (unknown), Suzanne Trudel, Annette E. Hay, Richard Leblanc, Michaël Sébag, Rayan Kaedbey, Julie Stakiw, Irwindeep Sandhu, (unknown), Philip Kuruvilla, (unknown), Graeme Quest, David P. McMullen, (unknown), Rami Kotb, Christopher P. Venner	0
2	Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population 2024 ·Blood ·(unknown), Irwindeep Sandhu, Michael P. Chu, Kathryn N. Rankin, Arleigh McCurdy, (unknown), (unknown), Edward H. Koo, (unknown), Sabrina Albert, (unknown), Christopher R. McCudden, Alissa Visram	0
3	A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma 2024 ·The Oncologist ·Hira Mian, Hsien Seow, (unknown), Matthew C. Cheung, (unknown), Jason Tay, Tanya M. Wildes, Arleigh McCurdy, Alissa Visram, Irwindeep Sandhu, Rinku Sutradhar	2
4	Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis 2024 ·Blood Advances ·(unknown), Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P. Venner, Irwindeep Sandhu, Arleigh McCurdy, Thierry Façon, María‐Victoria Mateos, Hira Mian	8
5	Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS 2024 ·Blood ·Ola Landgren, Ajai Chari, Yaël C. Cohen, Andrew Spencer, Peter M. Voorhees, Irwindeep Sandhu, Matthew Jenner, Dean Smith, Michèle Cavo, Niels W.C.J. van de Donk, Meral Beksaç, Philippe Moreau, Hartmut Goldschmidt, Diego Vieyra, Linlin Sha, L. Li, (unknown), (unknown), Robin Carson, Craig C. Hofmeister	1
6	A1 PRE-CLINICAL CROHN’S DISEASE MICROBIOME PROMOTES INFLAMMATION IN GNOTOBIOTIC RECIPIENT MICE 2024 ·Journal of the Canadian Association of Gastroenterology ·(unknown), Alice Chen-Liaw, Andrew A. Luchak, Irwindeep Sandhu, Kun Mu, Meilan Xue, (unknown), Ilaria Mogno, Catherine Streutker, (unknown), (unknown), Williams Turpin, Kenneth Croitoru	1
7	Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis 2024 ·Blood ·Saad Z. Usmani, Michał Mielnik, Mamta Garg, Irwindeep Sandhu, Al‐Ola Abdallah, Youngil Koh, Albert Oriol, Hang Quach, Katja Weisel, Aránzazu Alonso, Enrique M. Ocio, Wojciech Janowski, Chang‐Ki Min, Karthik Ramasamy, (unknown), Paula Rodríguez‐Otero, Chris Brawley, (unknown), Morrys C. Kaisermann, Marek Hus	3
8	Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Albert Oriol, Roman Hájek, Ivan Špıčka, Irwindeep Sandhu, Yaël C. Cohen, Moshe E. Gatt, José Mariz, Michèle Cavo, Jesús G. Berdeja, Kexin Jin, Merav Bar, (unknown), (unknown), (unknown), Deepak Perumal, Luciano J. Costa	0
9	Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study 2024 ·Haematologica ·Alissa Visram, Kelvin Chan, Hsien Seow, Gregory R. Pond, (unknown), Ghulam Rehman Mohyuddin, Arleigh McCurdy, Irwindeep Sandhu, Christopher P. Venner, Guido Lancman, (unknown), (unknown), (unknown), (unknown), Rafaël Fonseca, Hira Mian	0
10	Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma 2024 ·Blood ·(unknown), Jenna Eagles, Aimée A. Wong, Saumil Shah, (unknown), (unknown), Cecília Bonolo de Campos, Darrell White, Irwindeep Sandhu, Kevin Song, (unknown), Abir Khaled, Liqiang Yang, (unknown), Tony Reiman, Suzanne Trudel, Trevor J. Pugh	0
11	An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Iyare Izevbaye, Michael P. Chu, Irwindeep Sandhu, Joseph Brandwein, Raymond Lai, (unknown)	4
12	Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM) 2023 ·Hematological Oncology ·Neil L. Berinstein, Kees-Peter de Roos, (unknown), Rebecca F. McClure, (unknown), Mona Shafey, Alexandra Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A. Aljama, Jean-François Larouche, (unknown)	1
13	Exercise Preferences, Barriers, and Facilitators of Individuals With Cancer Undergoing Chemotherapy Before Stem Cell Transplantation 2023 ·Cancer Nursing ·(unknown), (unknown), (unknown), (unknown), Christopher M. Sellar, George J. Francis, (unknown), Edith Pituskin, (unknown), Sarah Perry, Irwindeep Sandhu, Christopher P. Venner, Margaret L. McNeely	1
14	Management of Multiple Myeloma: A Review for General Practitioners in Oncology 2023 ·Current Oncology ·(unknown), Irwindeep Sandhu, Ann Lee	17
15	Filgrastim-Induced Bone Pain Is More Prevalent and Severe during Stem Cell Mobilization 2021 ·Transplantation and Cellular Therapy ·Matthew Anaka, (unknown), (unknown), Anthea Peters, (unknown), Christopher P. Venner, Irwindeep Sandhu, Michael P. Chu	0
16	Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism 2021 ·Current Issues in Molecular Biology ·(unknown), (unknown), Jing Li, Christopher P. Venner, Irwindeep Sandhu, Anthea Peters, Afsaneh Lavasanifar, Raymond Lai	4
17	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model 2018 ·Cancers ·(unknown), Ommoleila Molavi, Abdulraheem Alshareef, (unknown), Qian Wang, Michael P. Chu, Christopher P. Venner, Irwindeep Sandhu, Anthea Peters, Afsaneh Lavasanifar, Raymond Lai	20
18	Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics 2017 ·Blood ·(unknown), David Sanford, Joseph Brandwein, Irwindeep Sandhu, Donna E. Hogge, (unknown)	2
19	The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data 2017 ·Blood ·(unknown), Irwindeep Sandhu, Michael P. Chu, (unknown), Ismail Ismail, Andrew R. Belch, Linda M. Pilarski, (unknown), Christopher P. Venner	2
20	The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort 2017 ·Blood ·(unknown), Víctor H. Jiménez‐Zepeda, Nizar J. Bahlis, Paola Neri, Irwindeep Sandhu, Michael P. Chu, Ismail Ismail, Jason Tay, Peter Duggan, Andrew Belch, (unknown), Linda M. Pilarski, (unknown), Christopher P. Venner	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact